JP2009502121A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009502121A5 JP2009502121A5 JP2008519739A JP2008519739A JP2009502121A5 JP 2009502121 A5 JP2009502121 A5 JP 2009502121A5 JP 2008519739 A JP2008519739 A JP 2008519739A JP 2008519739 A JP2008519739 A JP 2008519739A JP 2009502121 A5 JP2009502121 A5 JP 2009502121A5
- Authority
- JP
- Japan
- Prior art keywords
- lefty
- polypeptide
- recombinant
- domain
- derivative polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 72
- 229920001184 polypeptide Polymers 0.000 claims 71
- 102000004196 processed proteins & peptides Human genes 0.000 claims 71
- 239000000203 mixture Substances 0.000 claims 15
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 claims 14
- 101710194452 Growth/differentiation factor 11 Proteins 0.000 claims 14
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims 14
- 108010056852 Myostatin Proteins 0.000 claims 14
- 150000001413 amino acids Chemical group 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 208000035475 disorder Diseases 0.000 claims 9
- 238000006471 dimerization reaction Methods 0.000 claims 8
- 235000001014 amino acid Nutrition 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 206010028289 Muscle atrophy Diseases 0.000 claims 3
- 210000000577 adipose tissue Anatomy 0.000 claims 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 201000000585 muscular atrophy Diseases 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 102100034134 Activin receptor type-1B Human genes 0.000 claims 2
- 102100034135 Activin receptor type-1C Human genes 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 101000799189 Homo sapiens Activin receptor type-1B Proteins 0.000 claims 2
- 101000799193 Homo sapiens Activin receptor type-1C Proteins 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000037415 AIDS wasting syndrome Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims 1
- 208000003577 HIV wasting syndrome Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- -1 Nodal Proteins 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 102000043168 TGF-beta family Human genes 0.000 claims 1
- 108091085018 TGF-beta family Proteins 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 206010016165 failure to thrive Diseases 0.000 claims 1
- 208000020694 gallbladder disease Diseases 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 239000000710 homodimer Substances 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 230000037257 muscle growth Effects 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 208000018360 neuromuscular disease Diseases 0.000 claims 1
- 208000013315 neuromuscular junction disease Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69622605P | 2005-07-01 | 2005-07-01 | |
| PCT/US2006/026443 WO2007006025A2 (en) | 2005-07-01 | 2006-06-30 | Lefty, lefty derivatives and uses therof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009502121A JP2009502121A (ja) | 2009-01-29 |
| JP2009502121A5 true JP2009502121A5 (enExample) | 2009-08-13 |
Family
ID=37605233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008519739A Withdrawn JP2009502121A (ja) | 2005-07-01 | 2006-06-30 | Ｌｅｆｔｙ、Ｌｅｆｔｙ誘導体およびそれらの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7612040B2 (enExample) |
| EP (1) | EP1899369A2 (enExample) |
| JP (1) | JP2009502121A (enExample) |
| AU (1) | AU2006264339A1 (enExample) |
| CA (1) | CA2613320A1 (enExample) |
| WO (1) | WO2007006025A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8106004B2 (en) * | 2006-07-28 | 2012-01-31 | Children's Memorial Hospital | Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells |
| EP2412383A1 (en) * | 2006-07-28 | 2012-02-01 | Children's Memorial Hospital | Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells |
| CN104981250A (zh) * | 2012-10-24 | 2015-10-14 | 细胞基因公司 | 用于治疗贫血的方法 |
| US10117908B2 (en) | 2013-10-17 | 2018-11-06 | Grant Labs, Inc. | Suppression of cellular transformation and dysplasia by topical application of lefty |
| EP3439741A4 (en) | 2016-04-06 | 2020-05-06 | Acceleron Pharma Inc. | ALK7 ANTAGONISTS AND USES THEREOF |
| AU2019404719B2 (en) * | 2018-12-20 | 2022-06-02 | Chong Kun Dang Pharmaceutical Corp. | Fusion protein comprising human lefty a protein variants and use thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6683156B1 (en) * | 1996-08-27 | 2004-01-27 | University Of South Florida | Method for diagnosing selected adenocarcinomas |
| US6294662B1 (en) * | 1996-08-27 | 2001-09-25 | University Of South Florida | Nucleic acids encoding an endometrial bleeding associated factor (ebaf) |
| US5916751A (en) * | 1996-08-27 | 1999-06-29 | University Of South Florida | Method for the diagnosis of selected adenocarcinomas |
| WO1999006444A1 (en) * | 1997-07-31 | 1999-02-11 | The Johns Hopkins University Of School Of Medicine | GROWTH DIFFERENTIATION FACTOR, Lefty-1 |
| US6635480B1 (en) * | 1997-07-31 | 2003-10-21 | The Johns Hopkins University School Of Medicine | Growth differentiation factor, lefty-2 |
| US20020086351A1 (en) * | 1998-08-20 | 2002-07-04 | Reinhard Ebner | Human nodal and lefty homologues |
| WO1999050416A1 (en) * | 1997-09-30 | 1999-10-07 | Pharmacia & Upjohn Company | Tnf-related death ligand |
| US6027917A (en) * | 1997-12-10 | 2000-02-22 | Genetics Institute, Inc. | Bone morphogenetic protein (BMP)-17 and BMP-18 compositions |
| AU5087799A (en) * | 1998-07-06 | 2000-01-24 | Beth Israel Deaconess Medical Center | Methods of inhibiting proliferative diseases by inhibiting tgf-beta mediated angiogenesis |
| US6747004B1 (en) * | 1999-04-29 | 2004-06-08 | North Shore - Long Island Jewish Research Institute | Method for inducing growth and enhancing survival of nervous tissue |
| WO2002012336A2 (en) * | 2000-08-09 | 2002-02-14 | Curis, Inc. | TGF-β THERAPEUTICS, COMPOSITIONS AND METHODS OF USE |
| US6649588B1 (en) * | 2000-10-05 | 2003-11-18 | North Shore - Long Island Jewish Research Institute | Inhibition of TGF-β and uses thereof |
| CA2497047A1 (en) * | 2002-08-27 | 2004-03-11 | Compound Therapeutics, Inc. | Adzymes and uses thereof |
| WO2005033134A2 (en) * | 2003-09-30 | 2005-04-14 | Regeneron Pharmaceuticals, Inc. | Secreted protein therapeutics and uses thereof |
-
2006
- 2006-06-30 JP JP2008519739A patent/JP2009502121A/ja not_active Withdrawn
- 2006-06-30 US US11/479,181 patent/US7612040B2/en active Active
- 2006-06-30 WO PCT/US2006/026443 patent/WO2007006025A2/en not_active Ceased
- 2006-06-30 AU AU2006264339A patent/AU2006264339A1/en not_active Abandoned
- 2006-06-30 CA CA002613320A patent/CA2613320A1/en not_active Abandoned
- 2006-06-30 EP EP06786560A patent/EP1899369A2/en not_active Withdrawn
-
2009
- 2009-09-18 US US12/586,207 patent/US20100160225A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024113039A (ja) | 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用 | |
| RU2558301C2 (ru) | Полипептиды для связывания с "рецептором конечных продуктов гликирования", а также их композиции и способы, в которых они принимают участие | |
| JP2017533194A5 (enExample) | ||
| JP2013523184A5 (enExample) | ||
| HRP20170323T1 (hr) | Dopunski aktivin receptor polipeptidi i njihove upotrebe | |
| JP2005507637A5 (enExample) | ||
| CA3049023A1 (en) | Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr) | |
| JP2012509687A5 (enExample) | ||
| JP2012507299A (ja) | Ｌｉｇｈｔ標的分子およびその使用 | |
| CA3033082A1 (en) | In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use | |
| JP2009523459A5 (enExample) | ||
| JP2010529859A (ja) | ＴＧＦ−βＩＩ型受容体の２つのＴＧＦ−β結合ドメインを含有する融合タンパク質 | |
| CN110430890A (zh) | 激活素受体iia型变体及其使用方法 | |
| AU2013223801B2 (en) | Tumour necrosis factor receptor fusion proteins and methods of using the same | |
| JP2017514515A5 (enExample) | ||
| JP2020524661A (ja) | 胃抑制ペプチド受容体（ｇｉｐｒ）に対するアンタゴニスト結合タンパク質／ｇｌｐ−１受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法 | |
| JP2008521426A5 (enExample) | ||
| TW201706306A (zh) | 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體 | |
| JP2009510999A (ja) | キメラ治療剤 | |
| US20180127478A1 (en) | SINGLE CHAIN Fc-DIMER-HUMAN GROWTH HORMONE FUSION PROTEIN FOR IMPROVED DRUG DELIVERY | |
| JP2014517690A5 (enExample) | ||
| JP2009502121A5 (enExample) | ||
| JP2020521784A5 (enExample) | ||
| CA3224743A1 (en) | Fusion polypeptides for metabolic disorders | |
| JP2002533115A5 (enExample) |